JP2019504892A5 - - Google Patents

Download PDF

Info

Publication number
JP2019504892A5
JP2019504892A5 JP2018560705A JP2018560705A JP2019504892A5 JP 2019504892 A5 JP2019504892 A5 JP 2019504892A5 JP 2018560705 A JP2018560705 A JP 2018560705A JP 2018560705 A JP2018560705 A JP 2018560705A JP 2019504892 A5 JP2019504892 A5 JP 2019504892A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
nucleic acid
acid encoding
promoter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018560705A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019504892A (ja
Filing date
Publication date
Priority claimed from PCT/CN2016/087855 external-priority patent/WO2017133175A1/en
Application filed filed Critical
Publication of JP2019504892A publication Critical patent/JP2019504892A/ja
Publication of JP2019504892A5 publication Critical patent/JP2019504892A5/ja
Pending legal-status Critical Current

Links

JP2018560705A 2016-02-04 2017-01-26 癌治療のための改変哺乳類細胞 Pending JP2019504892A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2016073489 2016-02-04
CNPCT/CN2016/073489 2016-02-04
PCT/CN2016/087855 WO2017133175A1 (en) 2016-02-04 2016-06-30 Engineered mammalian cells for cancer therapy
CNPCT/CN2016/087855 2016-06-30
PCT/CN2017/072723 WO2017133633A1 (en) 2016-02-04 2017-01-26 Engineered mammalian cells for cancer therapy

Publications (2)

Publication Number Publication Date
JP2019504892A JP2019504892A (ja) 2019-02-21
JP2019504892A5 true JP2019504892A5 (enExample) 2020-03-05

Family

ID=59499323

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018560705A Pending JP2019504892A (ja) 2016-02-04 2017-01-26 癌治療のための改変哺乳類細胞

Country Status (5)

Country Link
US (1) US20190038671A1 (enExample)
EP (1) EP3411079A4 (enExample)
JP (1) JP2019504892A (enExample)
CN (1) CN108883202A (enExample)
WO (2) WO2017133175A1 (enExample)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
US9725710B2 (en) 2014-01-08 2017-08-08 Flodesign Sonics, Inc. Acoustophoresis device with dual acoustophoretic chamber
US10441654B2 (en) 2014-01-24 2019-10-15 Children's Hospital Of Eastern Ontario Research Institute Inc. SMC combination therapy for the treatment of cancer
US20170151281A1 (en) 2015-02-19 2017-06-01 Batu Biologics, Inc. Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
TW202436356A (zh) 2016-10-11 2024-09-16 美商艾吉納斯公司 抗ｌａｇ－３抗體及其使用方法
US11185586B2 (en) 2016-11-22 2021-11-30 Alloplex Biotherapeutics, Inc. Allogeneic tumor cell vaccine
WO2018098279A1 (en) 2016-11-22 2018-05-31 Alloplex Biotherapeutics Allogenic tumor cell vaccine
WO2018152572A1 (en) * 2017-02-21 2018-08-30 The University Of Adelaide T cells expressing chemokine receptors for treating cancer
CA3059634A1 (en) 2017-04-13 2018-10-18 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
EP3612222A4 (en) * 2017-04-19 2020-12-23 University of Southern California COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER
WO2019000223A1 (en) 2017-06-27 2019-01-03 Nanjing Legend Biotech Co., Ltd. ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
WO2019025800A1 (en) * 2017-08-02 2019-02-07 Autolus Limited CELLS EXPRESSING A CHIMERIC ANTIGENIC RECEPTOR OR A MANIPULATED TCR AND COMPRISING A SELECTIVELY EXPRESSED SELECTIVE NUCLEOTIDE SEQUENCE
GB201713078D0 (en) 2017-08-15 2017-09-27 Adaptimmune Ltd T Cell Modification
EP3679145A2 (en) 2017-09-08 2020-07-15 Poseida Therapeutics, Inc. Compositions and methods for chimeric ligand receptor (clr)-mediated conditional gene expression
WO2019077037A1 (en) * 2017-10-18 2019-04-25 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus METHODS AND COMPOUNDS FOR ENHANCED IMMUNE CELL THERAPY
JP2021507561A (ja) 2017-12-14 2021-02-22 フロデザイン ソニックス， インク．Ｆｌｏｄｅｓｉｇｎ Ｓｏｎｉｃｓ， Ｉｎｃ． 音響トランスデューサドライバ及びコントローラ
GB201721802D0 (en) * 2017-12-22 2018-02-07 Almac Discovery Ltd Ror1-specific antigen binding molecules
EP4279501A3 (en) * 2018-02-15 2024-02-28 The National Institute for Biotechnology in the Negev Ltd. Tumor environment-specific expression of chimeric antigen receptors
EP3766499A4 (en) * 2018-03-13 2021-04-21 Osaka University TUMOR IMMUNE STIMULATOR
AU2019253562B2 (en) * 2018-04-09 2025-11-27 The Trustees Of The University Of Pennsylvania Methods and compositions comprising a viral vector for expression of a transgene and an effector
CN110615842B (zh) * 2018-06-20 2023-05-09 上海隆耀生物科技有限公司 一种包含共刺激受体的嵌合抗原受体及应用
CN108913718A (zh) * 2018-07-20 2018-11-30 苏州茂行生物科技有限公司 一种靶向EGFR vⅢ的CAR-T细胞的制备方法及应用
CN108949825A (zh) * 2018-07-30 2018-12-07 苏州茂行生物科技有限公司 一种靶向her2的car-t细胞的制备方法及应用
US11866494B2 (en) * 2018-08-31 2024-01-09 Innovative Cellular Therapeutics Holdings, Ltd. CAR T therapy through uses of co-stimulation
JP7558151B2 (ja) * 2018-09-05 2024-09-30 アダプティミューン・リミテッド Ｔ細胞改変
CN112673022B (zh) 2018-09-10 2024-07-09 南京传奇生物科技有限公司 针对cd33的单结构域抗体及其构建体
US11419898B2 (en) 2018-10-17 2022-08-23 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
JP2022512766A (ja) 2018-10-17 2022-02-07 センティ バイオサイエンシズ インコーポレイテッド 組み合わせがん免疫療法
US12257286B2 (en) 2018-10-31 2025-03-25 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
WO2020092839A1 (en) 2018-10-31 2020-05-07 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
EP3876977A1 (en) 2018-11-06 2021-09-15 The Regents Of The University Of California Chimeric antigen receptors for phagocytosis
JP7571021B2 (ja) * 2018-12-06 2024-10-22 グアンドン ティーシーアールキュア バイオファーマ テクノロジー カンパニー リミテッド 腫瘍抗原、ＴＧＦ－β、および免疫チェックポイントを標的とする組み合わせＴＣＲ－Ｔ細胞療法
US12419913B2 (en) 2019-02-08 2025-09-23 Dna Twopointo, Inc. Modification of CAR-T cells
SG11202108665PA (en) * 2019-02-08 2021-09-29 Dna Twopointo Inc Transposon-based modifications of immune cells
WO2020172553A1 (en) * 2019-02-22 2020-08-27 Novartis Ag Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors
WO2020181221A1 (en) * 2019-03-07 2020-09-10 Children's Medical Center Corporation Targeted delivery of immune-modulating vhh and vhh-fusion protein
WO2020219504A1 (en) * 2019-04-23 2020-10-29 The Regents Of The University Of California Modulating survival of therapeutic cells and methods, cells and nucleic acids related thereto
US11013764B2 (en) 2019-04-30 2021-05-25 Myeloid Therapeutics, Inc. Engineered phagocytic receptor compositions and methods of use thereof
US20220291203A1 (en) * 2019-07-25 2022-09-15 Immunowake Inc. Methods of measuring cell-mediated killing by effectors
KR20220040476A (ko) * 2019-08-01 2022-03-30 메모리얼 슬로안 케터링 캔서 센터 개선된 면역치료법을 위한 세포 및 이의 용도
EP4022067A4 (en) * 2019-08-28 2023-12-20 Senti Biosciences, Inc. COMBINATORIAL CANCER IMMUNOTHERAPY
CN114981409A (zh) 2019-09-03 2022-08-30 美洛德生物医药公司 用于基因组整合的方法和组合物
MX2022004772A (es) * 2019-10-22 2022-07-19 Alloplex Biotherapeutics Composiciones y métodos para la activación y la expansión in vitro de poblaciones de linfocitos t citolíticos en serie e inmunización pasiva de un paciente de cáncer con células tumorales asesinas.
CN115297873A (zh) * 2019-11-08 2022-11-04 梅约医学教育与研究基金会 利用工程化改造的间充质干细胞治疗炎症和退行性疾病的方法和物质
CN112941028A (zh) * 2019-12-09 2021-06-11 上海细胞治疗集团有限公司 纳米抗体基因修饰的间充质干细胞及其制备方法与应用
US10980836B1 (en) 2019-12-11 2021-04-20 Myeloid Therapeutics, Inc. Therapeutic cell compositions and methods of manufacturing and use thereof
CA3164706A1 (en) * 2020-01-14 2021-07-22 Jonathan David SILK Method of treatment of cancer or tumour
IL295896A (en) * 2020-02-26 2022-10-01 Biograph 55 Inc c19 c38 bispecific antibodies
CN115335087A (zh) * 2020-04-01 2022-11-11 南京传奇生物科技有限公司 用于减少同种异体细胞疗法中的移植物排斥的组合物和方法
CN116096433A (zh) * 2020-06-29 2023-05-09 纪念斯隆凯特琳癌症中心 表达c825的免疫细胞及其诊断用途
AU2021334950A1 (en) * 2020-08-24 2023-03-02 Charité - Universitätsmedizin Berlin Chimeric antigen receptor (CAR)-expressing cells recognizing CEA
AU2021368557A1 (en) * 2020-10-27 2023-06-08 Adoc Ssf, Llc Compositions and methods for the treatment of cancer using next generation engineered t cell therapy
EP4240367A4 (en) 2020-11-04 2024-10-16 Myeloid Therapeutics, Inc. MODIFIED CHIMERIC FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF
US12234473B2 (en) 2020-12-31 2025-02-25 Immatics US, Inc. CD8 polypeptides, compositions, and methods of using thereof
CA3212398A1 (en) 2021-03-17 2022-09-22 Daniel Getts Engineered chimeric fusion protein compositions and methods of use thereof
CA3218780A1 (en) 2021-05-11 2022-11-17 Daniel Getts Methods and compositions for genomic integration
KR20240027025A (ko) * 2021-06-24 2024-02-29 조지아 테크 리서치 코포레이션 열 표적화에 의한 t 세포 요법의 원격 제어를 위한 방법 및 조성물
CN113789299B (zh) * 2021-10-18 2023-03-24 新鲁细胞生物科技(海南)有限公司 一种脐血nk细胞的体外增殖培养基、体外培养试剂盒和体外培养方法
WO2024077270A1 (en) * 2022-10-07 2024-04-11 Senti Biosciences, Inc. Armed chimeric receptors and methods of use thereof
WO2024107410A1 (en) * 2022-11-14 2024-05-23 The Board Of Trustees Of The Leland Stanford Junior University Cd39 selection for cytotoxicity of genetically engineered t regulatory cells
TW202440636A (zh) 2023-03-21 2024-10-16 美商傳記５５有限公司 Ｃｄ１９／ｃｄ３８多特異性抗體
FI131854B1 (en) 2023-05-29 2026-01-12 Onni Biotechnologies Oy Modified natural killer cells with enhanced cytotoxic activity and greater survival
WO2025081190A1 (en) * 2023-10-12 2025-04-17 Georgia Tech Research Corporation Image guided car t cell therapy to treat brain tumors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5215964A (en) * 1991-06-03 1993-06-01 Immunobiology Research Institute, Inc. Peptides useful in regulating the immune and nervous systems
JP2001521740A (ja) * 1997-11-03 2001-11-13 ジ・アリゾナ・ボード・オブ・リージェンツ・オン・ビハーフ・オブ・ザ・ユニバーシティ・オブ・アリゾナ 遺伝子治療用の高温誘導性発現ベクター及びその使用方法
CN1753912B (zh) * 2002-12-23 2011-11-02 惠氏公司 抗pd-1抗体及其用途
MX357691B (es) * 2006-01-13 2018-07-19 The Government Of The United States As Represented By The Secretary Of The Department Of Health And Il-15 y il-15r-alfa mejoradas para expresion en celulas mamiferas.
ES2716298T3 (es) * 2011-09-16 2019-06-11 Baylor College Medicine El microentorno tumoral como diana mediante el uso de células NKT manipuladas
PL2958943T3 (pl) * 2013-02-20 2020-04-30 The Trustees Of The University Of Pennsylvania Leczenie nowotworu złośliwego za pomocą humanizowanego chimerycznego receptora antygenowego anty-egfrviii
EP2961831B1 (en) * 2013-02-26 2020-06-10 Memorial Sloan Kettering Cancer Center Compositions and methods for immunotherapy
EP3119425B1 (en) * 2014-03-15 2020-09-23 Novartis AG Regulatable chimeric antigen receptor
DK3151672T3 (da) * 2014-06-06 2021-02-01 Bluebird Bio Inc Forbedrede t-celle-sammensætninger
EP3193915A1 (en) * 2014-07-21 2017-07-26 Novartis AG Combinations of low, immune enhancing. doses of mtor inhibitors and cars
EP3313883B1 (en) * 2015-06-23 2023-12-06 Memorial Sloan Kettering Cancer Center Novel pd-1 immune modulating agents

Similar Documents

Publication Publication Date Title
JP2019504892A5 (enExample)
Dougan et al. Cancer immunotherapy: beyond checkpoint blockade
Demaria et al. Harnessing innate immunity in cancer therapy
Mardi et al. Biological causes of immunogenic cancer cell death (ICD) and anti-tumor therapy; combination of oncolytic virus-based immunotherapy and CAR T-cell therapy for ICD induction
JP7162632B2 (ja) 細胞免疫療法前の細胞毒性プレコンディショニングの代替
West et al. PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells
JP2019500909A5 (enExample)
Zamarin et al. Potentiation of immunomodulatory antibody therapy with oncolytic viruses for treatment of cancer
Draghiciu et al. Therapeutic immunization and local low‐dose tumor irradiation, a reinforcing combination
JP2019501670A5 (enExample)
Huang et al. Innovative strategies to advance CAR T cell therapy for solid tumors
Cervera-Carrascon et al. Oncolytic adenoviruses: a game changer approach in the battle between cancer and the immune system.
AU2019379325A1 (en) Method of treating a tumor with a combination of IL-7 protein and an immune checkpoint inhibitor
JP2019531293A (ja) Ｐｄ−１ペプチド阻害剤
Hughes et al. Critical analysis of an oncolytic herpesvirus encoding granulocyte-macrophage colony stimulating factor for the treatment of malignant melanoma
JP2026015423A (ja) ＩＦＮ－γの抗腫瘍補助薬の調製への応用
Pieper et al. Radiation augments the local anti-tumor effect of in situ vaccine with CpG-oligodeoxynucleotides and anti-OX40 in immunologically cold tumor models
Hu et al. The limiting factors of oncolytic virus immunotherapy and the approaches to overcome them
Vo et al. Cellular immunotherapy in multiple myeloma
Guo et al. In situ extended immune activation instantly after tumor resection by oncolytic virus controls postoperative tumor recurrence
CA3168378A1 (en) Lypmphocyte population and methods for producing same
Msaouel et al. Immune checkpoint therapy in head and neck cancers
Schütz et al. MHC‐Ig induces memory T cell formation in vivo and inhibits tumour growth
Lasek et al. Interleukin 12: Antitumor activity and immunotherapeutic potential in oncology
CA3229529A1 (en) Lymphocyte population and methods for producing same